Successful treatment of ocular sarcoidosis with rituximab

Ocular Immunology and Inflammation

Volumn 21, Issue 3, 2013, Pages 244-246

  Beccastrini, Enrico ^a   Vannozzi, Lorenzo ^a   Bacherini, Daniela ^a   Squatrito, Danilo ^a   Emmi, Lorenzo ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE; INFLIXIMAB; PREDNISONE; RITUXIMAB; TROPICAMIDE;

ADULT; CASE REPORT; CONCURRENT INFECTION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ECHOGRAPHY; ENZYME BLOOD LEVEL; ERYTHEMA NODOSUM; EYE SYNECHIA; FEMALE; FOLLOW UP; GRANULOMATOSIS; HEPATITIS C; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRIDOCYCLITIS; LETTER; LUNG LESION; MEDIASTINUM LYMPHADENOPATHY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE; PARESTHESIA; PATIENT REFERRAL; RECURRENT DISEASE; REMISSION; RETINA MACULA CYSTOID EDEMA; RETREATMENT; SARCOIDOSIS; SCINTIGRAPHY; STEROID THERAPY; THORAX RADIOGRAPHY; TOPICAL TREATMENT; UVEITIS; VISUAL ACUITY; VITREOUS OPACITY; WHITE MATTER LESION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; EYE DISEASES; FEMALE; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; HUMANS; IMMUNOLOGIC FACTORS; MIDDLE AGED; SARCOIDOSIS;

EID: 84878429822     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2012.762982     Document Type: Letter

References (14)

1. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis and therapeutics. JAMA. 2011;305:391-399.
2. Pras E, Neumann R, Zandman-Goddard G, et al. Intraocular inflammation in autoimmune diseases. Semin Arthritis Rheum. 2004;34:602-609. (Pubitemid 39643122)
3. Levy RA, De Andrade FA, Foeldvari I. Cutting-edge issues in autoimmune uveitis. Clin Rev Allerg Immunol. 2011;41:214-233.
4. Theodossiadis PG, Lirakos VS, Sfikakis PP, et al. Intravitreal administration of the anti-TNF monoclonal antibody Infliximab in the rabbit. Graefes Arch Clin Exp Ophthalmol. 2009;247:273-281.
5. Giansanti F, Papucci L, Capaccioli S, et al. Ocular safety of Infliximab in rabbit and cell culture models. J Ocul Pharmacol Ther. 2010;26:65-71.
6. Farvardin M, Afarid M, Shahrzad S. Long-term effects of intravitreal Infliximab for treatment of sight threatening chronic noninfectious uveitis. J Ocul Pharmacol Ther. 2012; 28:628-631.
7. De Smet MD, Taylor SR, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res. 2011;30:452-470.
8. Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophtalmol. 2007;18:481-486. (Pubitemid 351339402)
9. Gottemberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005; 64:913-920. (Pubitemid 40733918)
10. Belkhou A, Younsi R, El Bouchti I, et al. Rituximab as a treatment alternative in sarcoidosis. Joint Bone Spine. 2008;7:698-699.
11. Dasilva V, Breuil V, Chevallier P, et al. Relapse of severe sarcoidosis with an uncommon peritoneal location after TNFa blockade: efficacy of rituximab, report of a single case. Joint Bone Spine. 2010;77:81-89.
12. Bomprezzi R, Pati S, Chansakul C, et al. A case of neurosarcoidosis successfully treated with rituximab. Neurology. 2010;75:568-570.
13. Miserocchi E, Modorati G. Rituximab for non-infectious uveitis. Dev Ophthalmol. 2012;51:98-109.
14. Bargagli E, Olivieri C, Rottoli P. Cytokine modulators in the treatment of sarcoidosis. Rheumatol Int. 2011; 31:1539-1544.